Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"SHINE Technologies","sponsor":"Fidelity Management and Research Company LLC","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Shine Closes $80-Million Series C Financing Supported by Fidelity Management and Research Company Llc","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ITM Enters Global Supply Agreements with Telix Pharmaceuticals for Clinical and Commercial Use of ITM\u2019s n.c.a. Lutetium-177","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Belgian Nuclear Research Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"POINT Biopharma Licenses Innovative Lu-177 Production Technology from SCK CEN (Belgian Nuclear Research Center)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals for Lutetium-177

    Menu

    Lutetium-177

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Point Biopharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              POINT Biopharma Licenses Innovative Lu-177 Production Technology from SCK CEN (Belgian Nuclear Research Center)

              Details:

              POINT is licensing SCK CEN’s n.c.a. Lu-177 purification technology to both further increase the resiliency of POINT’s supply chain, as well as to lower POINT’s cost of medical isotope, the most expensive raw material used in radiopharmaceutical production.

              Lead Product(s): PNT2002,Lutetium-177

              Therapeutic Area: Oncology Product Name: PNT2001

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Belgian Nuclear Research Center

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement November 24, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Isotope Technologies Munich

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ITM Enters Global Supply Agreements with Telix Pharmaceuticals for Clinical and Commercial Use of ITM’s n.c.a. Lutetium-177

              Details:

              Telix has extended its non-exclusive global clinical and commercial supply agreements with Garching-based ITM AG for the supply of highly pure no-carrier-added lutetium-177 , a therapeutic isotope used in Telix’s portfolio of Molecularly Targeted Radiation products.

              Lead Product(s): Lutetium-177,Undisclosed

              Therapeutic Area: Oncology Product Name: DP-3311

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Telix Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement March 18, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SHINE Technologies

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Shine Closes $80-Million Series C Financing Supported by Fidelity Management and Research Company Llc

              Details:

              Fuding will support SHINE's continued effort to make strong progress in their work to commercialize molybdenum-99, an essential diagnostic isotope, and lutetium-177, a therapeutic isotope that is showing great promise for the treatment of cancer.

              Lead Product(s): Lutetium-177

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: Fidelity Management and Research Company LLC

              Deal Size: $80.0 million Upfront Cash: Undisclosed

              Deal Type: Series C Financing September 02, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY